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Mathematical modelling of radiation-induced cancer risk from breast screening by 
mammography  
Abstract 
Objectives: Establish a method to determine and convey lifetime radiation risk from FFDM 
screening. 
Methods: Radiation risk from screening mammography was quantified using effective risk 
(number of radiation-induced cancer cases/million). For effective risk calculations, organ doses 
and examined breast MGD were used. Screening mammography was simulated by exposing a 
breast phantom for cranio-caudal and medio-lateral oblique for each breast using 16 FFDM 
machines. An ATOM phantom loaded with TLD dosimeters was positioned in contact with the 
breast phantom to simulate the client’s body. Effective risk data were analysed using SPSS 
software to establish a regression model to predict the effective risk of any screening 
programme. Graphs were generated to extrapolate the effective risk of all screening programmes 
for a range of commencement ages and time intervals between screens. 
Results: The most important parameters controlling clients’ total effective risk within breast 
screening are the screening commencement age and number of screens (correlation coefficients 
were -0.865 and 0.714, respectively). Since the tissue radio-sensitivity reduces with age, the end 
age of screening does not result in noteworthy effect on total effective risk.   
Conclusions: The regression model can be used to predict the total effective risk for clients 
within breast screening but it cannot be used for exact assessment of total effective risk. 
Graphical representation of risk could be an easy way to represent risk in a fashion which might 
be helpful to clients and clinicians. 
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Introduction 
Radiation risk refers to the damage produced by ionising radiation due to energy deposition in 
tissues. The amount of damage is related to radiation dose, radiation source (e.g. whether it is 
internal or external), length of time of exposure, which organs are exposed to radiation and the 
individual’s sensitivity which is influenced by age and gender [1]. Adverse health effects as a 
result of exposure to radiation can be classified into two groups: deterministic which follow high 
radiation doses and result in direct and predictable tissue damage; stochastic effects which follow 
low radiation doses and may result in cancer development [2].  
There are two opposing risk models to estimate the risk from low radiation doses. The first 
adopts the linear no-threshold principle. According to this model any dose, no matter how small, 
can result in cancer. The second model proposes that there is a specific threshold for radiation-
induced cancer, and below this threshold the radiation dose can be considered as safe [3].  It has 
been suggested that the best reasonable risk model to describe the relationship between the 
exposure to low energy radiation and solid cancers incidence is the linear no-threshold model 
(LNT) [2, 4]. 
In 2010, the Health Protection Agency (HPA) reported that medical and dental X-ray procedures 
constituted 90% of man-made radiation sources to the United Kingdom (UK) population [5]. 
However, the medical radiation exposure to the United States (US) population increased by 
600% from 1980 to 2012 [6]. Accordingly, there is a growing need for healthcare professionals 
to be more conscious of the risks associated with imaging when using ionising radiation for 
diagnostic purposes [7]. This is particularly true for mammography breast screening programmes 
where asymptomatic women are imaged [8]. Also, when screening frequency is increased, 
because of increased risk of breast cancer [9], radiation risk also increases as a direct 
consequence of mammography imaging. Extra diligence should therefore be exercised when 
assigning a woman into a high risk cancer category in which more frequent mammography 
screening is required. Overall, the radiation risk from screening mammography is considered to 
be low [10, 11].  Nevertheless, the health profession needs to understand the radiation risks to the 
woman from mammography imaging, in order to justify serial imaging at any frequency level.  
To date, radiation risk has tended to be expressed in terms of dose to the breast (mean glandular 
dose, MGD) which can be a difficult concept to understand by some imaging staff and referring 
clinicians. Equally the woman has to make an informed decision about participating in screening 
taking into account the potential harm the radiation might bring against the benefit of the 
programme [12].  
The work presented here applies previously published data by M.Ali et al. [13] which measured 
the direct absorbed radiation dose from the examined breast, contralateral breast and 19 other 
organs across 16 FFDM machines to estimate lifetime effective risk of radiation induced cancer 
for the UK Breast Screening Programme.  Here we develop the model further to establish a 
method for estimating & conveying lifetime induced cancer risk from breast cancer screening 
(from FFDM) for an average woman, with average breast size and density across a lifetime for a 
range of different FFDM screening scenarios. The method proposed is comprehendible and can 
be used by referring clinicians and breast screening organisations worldwide in the justification 
process and during the development of recommendations. Further, women will be able to make 
an informed decision on whether to attend breast screening.  
Method 
To calculate effective risk, organ dose data was required for all four mammography projections 
along with lifetime attributable risk (LAR) factors for all ages that screening takes place ranging 
from 25 years, the earliest probable age of screening for high risk clients in the US, to 75 years 
the latest age of screening end worldwide [13]. Two breast phantoms, attached to an adult 
dosimetry phantom, were exposed on 16 FFDM machines (Table 1) located in breast screening 
services within the UK. MGD was calculated; all other organ doses were measured directly using 
thermoluminescent dosimeters (TLD) as reported previously by M.Ali et al. [13]. LAR factors 
were calculated for a range of ages using a linear extrapolation method. Dose and LAR data were 
analysed to generate scenarios in order to calculate total effective lifetime risk values. 
Phantoms 
To replicate simulated breast thickness and shape in different positions, two breast phantoms 
constructed of polymethyl methacrylate- polyethylene (PMMA-PE) slabs were used. The Cranio-
caudal (CC) phantom was semi-circular of 95mm diameter  and 53mm thickness (32.5mm 
PMMA and 20.5mm PE); the medio-lateral oblique (MLO) was rectangular of 100×150 mm2 
area and 58mm thickness (32.5mm PMMA and 25.5mm PE). These breast phantoms simulate an 
average breast thickness with 29% breast density [14, 15]. According to Yaffe et al. this density 
can be considered as the common breast density because they found that 95% of 2831 Canadian 
women have a breast density of less than 45% [16]. 280 calibrated TLD-100H dosimeters 
(Thermo Scientific, USA) were accommodated inside an adult ATOM dosimetry phantom (CIRS 
Inc, Norfolk, Virginia, USA)  to measure the radiation dose received by 20 different body organs 
(indicated in Figure 3). Harshaw TLD-100H dosimeters can measure radiation doses across a 
wide range (1 pGy-10 Gy) with linear response at this energy range (according to the 
manufacture guidelines [17]. The total uncertainty, due to sensitivity difference and consistency, 
associated with the detector readings is less than 5%. The ATOM phantom was positioned in 
contact with the breast phantom to simulate the female body (Figure 1). MGD was calculated 
using the Institute of Physics and Engineering in Medicine (IPEM) method [18], which is based 
on the work published by Dance et al. [19]. 
Exposing the phantom 
The breast phantoms (and ATOM phantom) were exposed on 16 FFDM machines (see Table 1); 
exposures were repeated 3 times on each occasion and then averaged to minimise random error. 
Since the full automatic exposure control (including kV, mAs and target/filter combination) is 
recommend by the European commission [20], full automatic exposure control was used to 
expose the breast phantoms on each occasion.     
Calculation of lifetime effective risk 
Organ doses together with tissue specific LAR for the US population (BEIR VII  phase 2 report) 
[4] were used to calculate effective risk from 25 to 75 years, using Brenner’s equation [21].  
R=∑rTHT 
Where R is the effective risk, rT is the cancer LAR for tissue T per unit equivalent dose of that 
tissue, and HT is the equivalent dose for tissue T. For each organ, the radiation dose was 
determined by averaging organ dose values from the sixteen FFDM machines. For breast tissue a 
total of both examined breast MGD and contralateral breast dose were used.  
Since LAR factors are published for each decade of life and our method requires the tissue LAR 
value for each year it was necessary to estimate LAR values for the missing years. A linear 
relationship between LAR value for each decade of life was used (Figure 2).  
Data analysis 
In order to get good statistical power, two hundred and seventy four different screening scenarios 
were proposed which comprised of different commencement / end ages (25-75 years) and 
screening frequencies. For each proposed lifetime interval, such as 25-75 years, 30-75 years, and 
30-70 years, we scheduled three different screening categories with regard to screening 
frequency (annual, biennial, or triennial).  Lifetime risk data, arising from the 274 scenarios were 
analysed in SPSS software (version 22.0, IBM, Armonk, New York, USA) to generate a 
mathematical regression model and relationship establishment between total effective risk and 
number of screens and commencement / end ages. The standard error of the estimate was 
calculated using SPSS software as the square root of the residual mean square to provide a 
measure of prediction accuracy of the regression model. Spearman’s correlation was used to 
determine the effect of screening commencement age, screening ending age and number of 
screens on effective lifetime risk. The statistical significance of each correlation was tested using 
a t-test. To improve accuracy,  for each screening frequency (annual, biennial, triennial) a 
relationship graph between screening commencement age and total effective risk has been 
obtained considering the screening ending age is constant at 75 years. For each graph 50 
different screening scenarios were proposed; the screening commencement age ranged from 25-
74 year.  
 
 
Results 
The total MGD, for both CC and MLO views, for the sixteen considered FFDM machines was 
2.019 (1.871-2.166) mGy; mean (95% CI). The minimum recorded MGD was 1.678 mGy, while 
the maximum MGD was 2.806 mGy. Despite these differences, all values were within the 
acceptable range recommended by national mammographic protocols [20].   
For organs other than the examined breast, it was found that for some organs the radiation dose 
was zero. This means that either these organs did not receive radiation dose during screening 
mammography exposure or the dose received by these organs was below the sensitivity threshold 
of the TLDs. However, some organs received radiation dose ranging from less than 1µGy to 
more than 25 µGy (Figure 3). The contralateral breast tissue received the second highest 
radiation dose after the examined breast; 28.75 [24.20 - 33.3] µGy (mean [95% CI]). However, 
sternum bone marrow radiation dose was the highest bone marrow dose and the third highest 
organ dose after the examined and contralateral breasts; 19.07 [15.81 - 22.34] µGy (mean [95% 
CI]). 
For each year of female lifetime the mean effective lifetime risk from one screening visit, along 
with the 95% confidence interval (CI) for the 16 FFDM machines is included in Table 2. The 
effective lifetime risk is shown to decrease with age. 
The effect of screening commencement age, number of screens and ending age of screening on 
the total effective risk was evaluated using Spearman’s correlation coefficient (Table 3). There is 
strong correlation between the total effective risk and both screening commencement age and 
number of screens during female lifetime.  
Using SPSS, a backward stepwise regression model was generated to predict the total effective 
risk of any screening programme with regard to commencement / end ages of screening and 
number of screens. The regression model is summarised in Table 4. The regression equation 
elucidates the effect magnitude of each parameter on effective lifetime risk. The validity of any 
regression model is determined by its ability to assess the outcome (total effective risk) 
variability by predictors’ variability (adjusted R2), and the interval of predicted outcome 
(variation coefficient).  
If screening mammography ending age is set at a constant level (75 years old), the factors that 
affect the total effective risk reduced down to only two (commencement age and screening 
frequency). The resultant graphical relationship between screening commencement age (year) on 
the X-axis and average total effective risk (case/106) for the sixteen FFDM machines on the Y-
axis is demonstrated in Figure 4 which contains three relationship lines; one for each screening 
frequency (annual, biennial, and triennial). 
 
Discussion 
Several researchers have assessed the radiation dose to other body tissues and organs from 
mammography; here other refers to all organs with the exclusion of the examined breast. In all 
instances, their approaches were different to the methods used here. For instance, Sechopoulos, 
Suryanarayanan , Vedantham , D’Orsi, and Karellas [22] used Monte Carlo dose simulation, 
while Hatziioannou et al. [23] used TLDs accommodated inside Lucite phantom to measure 
radiation dose received by several organs during cranio-caudal and medio-lateral breast 
exposures. Organ radiation doses measured in this work showed some differences between the 
sixteen FFDM machines (Figure 3). For instance, for some FFDM machines the third highest 
other organ radiation dose was received by clavicular bone marrow (after contralateral breast and 
sternum bone marrow), while for other machines the thyroid radiation dose ranks as the third 
highest dose. However, these organ dose differences do not result in large variations in 
calculated total effective lifetime risk because examined breast MGD results in up to 98% of 
effective lifetime risk and other organs cause only 2%.      
Statistical analysis illustrates that there is a strong correlation between total effective risk and 
both screening commencement age and number of screens. The correlation coefficients were -
0.865 and 0.714, respectively. This means that the total effective risk increases with early 
screening commencement age and a greater number of screens. However, a weak correlation is 
seen between the total effective risk and the end age of screening (-0.346). This suggests that for 
any screening programme the total effective risk decreases with increased end age of screening.  
The regression model can be used to predict the total effective risk for any screening programme 
by the screening commencement age, number of screens and ending age of screening. However, 
any regression model has an associated error. Our regression model can explain 87% of total 
effective risk variability by other parameter variability (adjusted R2 = 0.87). For prediction 
purposes, the predicted total effective risk intervals are wide, with a coefficient of variation for 
the model around 31%. The addition of time interval between screens as a predictor to the 
regression model does not increase the model’s accuracy; its effect is statistically non-
significant. 
For accurate calculation of total effective risk for any screening programme we established a 
relationship graph (Figure 4).  To generate the graph, effective risk data for ages 25-75 years 
were used to propose different screening scenarios with regards to the screening commencement 
age and time interval between screens, these were the most important factors affecting the 
radiation effective risk. The proposed commencement ages ranged from 25 years, the earliest 
probable age of screening mammography for high risk women, to 74 years. One, two, and three 
year time intervals were considered in our scenarios. Since human tissue radio-sensitivity 
reduces greatly after age of 70 years and most worldwide screening programmes end between the 
ages 70-75 years [24], the ending age of screening mammography does not generate large 
differences in calculated total effective lifetime risk. Accordingly, the ending age of screening 
mammography was considered as 75 years in all of our scenarios. The graph comprises of three 
lines, one for each time interval, so it can be easily used to evaluate the total effective risk of any 
screening programme by the commencement age of screening using interpolation method. 
The main advantage of our graphical data is that they represent an easy way for radiation risk 
estimation from screening mammography to be illustrated. The graph can be simply used by 
clinicians/referrers or practitioners, and the graphical data are more likely to be understandable 
by the women than MGD. It is useful for screening mammography justification in terms of 
harms versus benefits especially for high breast cancer risk women who are invited for early and 
more frequent screening mammography than average breast cancer risk women. Moreover, the 
radiation risk to other body tissues and organs are included in this model. 
The major limitation of our model is that it was generated for an average size woman who has an 
average breast thickness and density. Accordingly our data are applicable for a breast with 29% 
density and 53 mm CC thickness. Thicker and more dense breasts require higher exposure 
factors (kV and mAs) resulting in higher MGD and consequently more risk of radiation-induced 
breast cancer. This limitation can be addressed by future work using different size body 
phantoms with a series of breast phantoms simulating a range of breast thicknesses and densities. 
Since FFDM is the only available technique for screening in the UK, this model was designed to 
assess the radiation risk when FFDM used. However, other mammographic modalities 
(computed radiography and film screen mammography) were not considered. Finally, the LAR 
factors used in the model generation were for Euro-American population. Accordingly, further 
work is required for other populations.  
A further limitation of our model is that it does not take into account genetic factors which 
increase the risk of developing breast cancer. Clinically, of these breast cancer susceptibility 
genes, BRCA1 and BRAC2 are most important. The risk of developing breast cancer among 
mutation carriers of these genes by the age of 70 is 65% and 45% respectively [25]. In order to 
address this issue, we are preparing a study on the impact of these and other genetic factors. 
Adding these factors to our statistical model as a covariate may lead to a refinement of our model 
and ultimately to a more accurate estimation of the true impact of mammography screening on 
the total effective risk.  
Overall our method can be used to establish a mathematical model for radiation risk assessment 
from any screening procedure involving ionising radiation such as breast cancer screening using 
digital breast tomosynthesis or dedicated breast computed tomography. The incorporation of 
breast density, breast size, genetic factors and different screening procedures (involving ionising 
radiation) into the model would enable the estimation of risk to be personalised for individual 
screening clients. This is the subject of our future work.    
 
 
Conclusion 
The multiple linear regression models can be considered useful for the prediction of the 
radiation-induced cancer from screening programmes for an average woman, albeit with a 
variation of 31%. Graphical representation of data, based upon scenarios, will have a value for 
informing clinicians/referrers and screening clients about the radiation risks from FFDM 
screening as the information is presented in a form which is easily understood compared with 
MGD. 
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                              (1a)                                                                             (1b) 
Figure (1) Breast and ATOM phantoms positioned on FFDM machine (a) in cranio-caudal 
position (b) in medio-lateral oblique position. 
 
Table (1) Study FFDM machines. 
Machine Brand 
Target/filter 
combination 
Number of 
machines 
Hologic Selenia  Mo/Mo 1 
Hologic Selenia Rh/Rh 2 
Hologic Selenia Dimensions  W/Rh 2 
GE Seno Essential  Rh/Rh 8 
Giotto  W/Ag 1 
Siemens Mammomat Inspiration W/Rh 2 
Total 16 
 
 
 
 
 Figure (2) Breast tissue LAR extrapolation using linear relationship between each decade LAR 
values. 
 
 
Figure (3) The mean organ doses across the sixteen FFDM machines (circles) with 95% CI 
(error bars) for one screening visit (CC and MLO projections for each breast) as measured using 
TLDs. 
Table (2) Mean calculated effective lifetime risk values for each year of female life with 95% 
CI. The 95% CI reflects variation in absorbed dose from the 16 FFDM machines. 
Age 
(year) 
Effective lifetime risk 
(case/106) 
Age 
(year) 
 Effective lifetime risk 
(case/106) 
Mean 95% CI Mean 95% CI 
25 70.0 [64.9 - 75.1] 51 13.6 [12.6 - 14.6] 
26 66.4 [61.5 - 71.2] 52 12.8 [11.9 - 13.8] 
27 62.8 [58.2 - 67.4] 53 12.0 [11.1 - 12.9] 
28 59.2 [54.8 - 63.5] 54 11.2 [10.4 - 12.0] 
29 55.5 [51.5 - 59.6] 55 10.4 [9.7 - 11.2] 
30 51.9 [48.1 - 55.7] 56 9.6 [8.9 - 10.3] 
31 49.6 [46.0 - 53.3] 57 8.8 [8.2 - 9.5] 
32 47.3 [43.9 - 50.8] 58 8.0 [7.4 - 8.6] 
33 45.0 [41.8 - 48.3] 59 7.2 [6.7 - 7.8] 
34 42.7 [39.6 - 45.9] 60 6.4 [6.0 - 6.9] 
35 40.5 [37.5 - 43.4] 61 6.0 [5.6 - 6.5] 
36 38.2 [35.4 - 41.0] 62 5.6 [5.2 - 6.1] 
37 35.9 [33.2 - 38.5] 63 5.3 [4.9 - 5.6] 
38 33.6 [31.1 - 36.0] 64 4.9 [4.5 - 5.2] 
39 31.3 [29.0 - 33.6] 65 4.5 [4.1 - 4.8] 
40 29.0 [26.9 - 31.1] 66 4.0 [3.8 - 4.4] 
41 27.5 [25.5 - 29.5] 67 3.7 [3.4 - 4.0] 
42 26.1 [24.2- 28.0] 68 3.3 [3.1 - 3.5] 
43 24.6 [22.8 - 26.4] 69 2.9 [2.7 - 3.1] 
44 23.2 [21.5 - 24.8] 70 2.5 [2.3 - 2.7] 
45 21.7 [20.1 - 23.3] 71 2.3 [2.2 - 2.5] 
46 20.2 [18.8 - 21.7] 72 2.2 [2.0 - 2.3] 
47 18.8 [17.4 - 20.2] 73 2.0 [1.9 - 2.2] 
48 17.3 [16.1 - 18.6] 74 1.8 [1.7 - 2.0] 
49 15.9 [14.7 - 17.0] 
75 1.7 [1.6 - 1.8] 
50 14.4 [13.4 - 15.5] 
CI, confidence intervals.  Effective lifetime risk refers to an individual’s chance 
of acquiring a radiation-induced cancer.   
 
 
 
 
 
 
 
 
Table (3) The association of different parameters with effective lifetime risk determined by 
Spearman’s correlation coefficient.  Statistical significance was tested using t-test. 
 
Commencement age Ending age Number of screens 
-0.865 -0.346 0.714 
All values were statistically significant (P<0.001). 
 
 
 
 
 
 
Table (4) Multiple linear regression equation. The standard error of the estimate was calculated 
in SPSS as the square root of the residual mean square. 
 
Regression Equation 
Adjusted 
R2 
Std. Error of 
Estimate 
Variation 
Coefficient 
TR= 705.170 –7.763 C – 6.085 E + 17.569 N 0.870  91.127  0.312 
TR, total effective lifetime risk; N, number of screens; C, commencement age of 
screening; E, ending age of screening. 
 
  
Figure (4) Total effective lifetime risk of screening mammography ending at age of 75 years 
(data based on calculated total effective risk of 50 scenarios of different commencement age for 
each screening frequency) 
